Lataa...
Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
Although proteasome inhibition with bortezomib (BTZ) is a validated treatment for relapsed or refractory mantle cell lymphoma (MCL), many patients show resistance to BTZ. However, the molecular mechanism of BTZ resistance in MCL has not been elucidated. In the present study, we investigated BTZ-resi...
Tallennettuna:
| Julkaisussa: | Oncotarget |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Impact Journals LLC
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4741995/ https://ncbi.nlm.nih.gov/pubmed/26517678 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|